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Abstract
Neuroectodermal tumor cells, like neural crest (NC)
cells, are pluripotent, proliferative, and migratory. We
tested the hypothesis that genetic programs essential
to NC development are activated in neuroectodermal
tumors. We examined the expression of transcription
factors PAX3, PAX7, AP-2A, and SOX10 in human
embryos and neuroectodermal tumors: neurofibroma,
schwannoma, neuroblastoma, malignant nerve sheath
tumor, melanoma, medulloblastoma, supratentorial pri-
mitive neuroectodermal tumor, and Ewing’s sarcoma.
We also examined the expression of P0, ERBB3, and
STX, targets of SOX10, AP-2A, and PAX3, respectively.
PAX3, AP-2A, and SOX10 were expressed sequentially
in human NC development, whereas PAX7 was re-
stricted tomesoderm. Tumors expressed PAX3, AP-2A,
SOX10, and PAX7 in specific combinations. SOX10
and AP-2A were expressed in relatively differentiated
neoplasms. The early NC marker, PAX3, and its homo-
logue, PAX7, were detected in poorly differentiated
tumors and tumors with malignant potential. Ex-
pression of NC transcription factors and target genes
correlated. Transcription factors essential to NC devel-
opment are thus present in neuroectodermal tumors.
Correlation of specific NC transcription factors with
phenotype, and with expression of specific downstream
genes, provides evidence that these transcription
factors actively influence gene expression and tumor
behavior. These findings suggest that PAX3, PAX7,
AP-2A, and SOX10 are potential markers of prognosis
and targets for therapeutic intervention.
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Introduction
Embryonic neural crest (NC) cells and cancer cells both
migrate from their sites of origin, proliferate, and colonize
distant sites in specific locations. The normal process of
NC development, in which primitive, pluripotent, migratory cells
give rise to diverse mature tissues, is partly reversed when,
within these tissues, malignancies arise. We propose that the
similarity between NC cells and neoplastic cells of NC-derived
tissues is not merely superficial, but rather reflects an inappro-
priate activation of genetic instructions used in NC develop-
ment. We tested two predictions of this theory: genes that
control NC development would be expressed in more primitive
tumors. We determined a set of transcription factors essential
for NC development and sequentially expressed as NC cells
mature. We then analyzed the expression of these markers in
tumors of NC-derived tissues, of varying growth dysregulation
and malignant potential. As proteins crucial to NC development
are expressed in embryonic neuroectoderm prior to NC dif-
ferentiation, we also tested the hypothesis that these proteins
are present in tumors with primitive neuroectodermal tumor
(PNETs) histology. Lastly, to test whether NC transcription
factors detected in neuroectodermal tumors actively influenced
tumor phenotype, we analyzed the expression of known down-
stream target genes.
The transcription factors AP-2a, PAX3, and SOX10 are
expressed in embryos by NC-derived cells, and each of these
proteins is required for normal NC development [1–5]. The
temporal expression patterns of these proteins, however, vary
significantly. PAX3 is expressed by NC precursors prior to
neurulation, and is required to maintain their competence for
NC induction [7,8]. AP-2a expression begins later than that
Abbreviations: NC, neural crest; NT, neural tube; MBL, medulloblastoma; SPNET, supra-
tentorial primitive neuroectodermal tumor; MNST, malignant nerve sheath tumor; SHH, sonic
hedgehog
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of PAX3 in premigratory NC cells [9]. Later in develop-
ment, PAX3 and AP-2a are downregulated in NC-derived
cells [7,9], except melanocytes [10,11]. SOX10, in contrast,
is expressed only by migratory NC-derived cells, and per-
sists in terminally differentiated melanocytes and glia [12].
We used the overlapping expression patterns of PAX3,
AP-2a, and SOX10 both to identify NC-derived cells and
to gauge their level of development. We also analyzed the
expression of PAX7, a protein homologous to PAX3 that
in mice is expressed in the mesoderm and in the mesecto-
dermal subset of cranial NC cells [6]. We thus used PAX7
as a marker of mesodermal and mesectodermal phenotype.
Several lines of evidence indicate that PAX3, AP-2a,
SOX10, and PAX7 regulate cell proliferation, survival, and
differentiation, both in development and in neoplasia. PAX3
and PAX7 promote survival in embryonic andmalignant cells,
whereas experimentally decreased PAX7 [13] or PAX3
[13–15] expression leads to cell death in embryonal rhab-
domyosarcoma [13], melanoma, and myoblast [14] cells.
Roles have also been proposed for PAX3 in promoting
metastasis [16] and opposing differentiation [17]. Studies
on transgenic mice lacking AP-2a have indicated that this
protein promotes the survival of normal embryonic cells, in-
hibits apoptosis, and promotes proliferation [2,18]. Studies
of human cancers, however, suggest that AP-2a may act as
a tumor suppressor [19–22]. Studies of SOX10 / mice
have demonstrated that SOX10 is essential for survival of
NC-derived cells and for glial differentiation [23]. Studies
of induced SOX10 expression in NC-derived stem cells
in vitro have demonstrated that SOX10 maintains these
cells in a multipotent, proliferative state, while permitting glial
differentiation [24]. These findings suggest a variety of
mechanisms by which PAX3, PAX7, AP-2a, and SOX10
might exert clinically significant effects on the behavior of
malignant cells.
As an initial measure of the effect of expressing SOX10,
AP-2a, and PAX3, we examined the expression of genes
known to be regulated by these transcription factors. Targets
of SOX10 include P0 and MITF [25,26]. AP-2a enhances the
expression of ERBB2 and ERBB3 [27]. Mayanil et al. [28]
identified several genes upregulated by PAX3, including
MYOD and STX.
The current investigation is intended to build on previous
work by other investigators, in which transcripts encod-
ing AP-2a, PAX3, PAX7, and SOX10 have individually
been detected in cell lines or malignant tumors [12,14,17,
19–22,29]. In accord with our hypotheses, we detected
NC markers AP-2a, PAX3, PAX7, and SOX10 in specific
combinations in human NC cells and in human tumors.
These combinations varied according to types of tumor
and their clinical features. Kho et al. [30] recently used micro-
array analysis of mRNA to demonstrate similarities in gene
expression in medulloblastoma (MBL) and early postnatal
cerebellum, supporting the idea that these tumors inappro-
priately activate developmental programs. Our findings simi-
larly support the hypothesis that, in their malignant behavior,
neuroectodermal tumor cells draw on the developmental
program of their ontologic ancestors. The transcription fac-
tors that direct this program in normal development are both
potential markers of prognosis and candidate targets for
therapeutic intervention.
Materials and Methods
All tissues were obtained by surgical resection. Specimens
were obtained from the archives of the Memorial Sloan Ket-
tering Cancer Center (MSKCC), Department of Pathology
(New York, NY) and the New York Presbyterian Hospital
(NYPH), Presbyterian Campus, Department of Pathology
(New York, NY). Total RNA from neuroblastomas was puri-
fied from snap-frozen tissue resected at MSKCC, whereas
total RNA from MBLs was generously provided by Dr. James
M. Olson (Fred Huchinson Cancer Research Center, Seat-
tle, WA). The use of human tissue specimens was reviewed
and approved by the Columbia University/NYPH and MSKCC
Institutional Review Boards. For immunocytochemistry, the
tissue was fixed in neutral-buffered formalin overnight, then
dehydrated and embedded in paraffin. Sections were cut to
a thickness of 4 to 6 mm and placed on treated slides.
For immunocytochemistry, tissue sections were prepared
by immersion in xylene, rehydration in ethanol, treatment
with 0.3% hydrogen peroxide in methanol, and heating in
10 mM citrate buffer, pH 5.5, in a microwave oven on high
power for 10 minutes. The tissue was incubated with 3%
serum and then incubated overnight with primary antibodies,
diluted, if necessary with phosphate-buffered saline with
0.3% Triton X (PBS-TX). Sections were then washed and
incubated for 2 to 16 hours with biotinylated or fluorophore-
conjugated secondary antibodies, diluted 1:200. After washes,
sections were incubated with avidin conjugated either to
horseradish peroxidase (HRP) or a second fluorophore. HRP-
labeled slides were stained with 0.05% diaminobenzidine
(DAB) as recommended in the AB Peroxidase Kit (Vector,
Burlingame, CA). Sections were counterstained with Gill’s
hematoxylin or, for immunofluorescence, with bisbenzamide.
Several primary antibodies were used. For SOX10, poly-
clonal antibodies, raised in goat (used diluted 1:100), were
generously provided by Santa Cruz Biotechnology (Santa
Cruz, CA; sc-17342, sc-17343), and a mouse monoclonal
antibody (used diluted 1:10) was generously provided by
Dr. David Anderson (California Institute of Technology,
Sacramento, CA). The SOX10 polyclonal and monoclonal
antibodies were tested on all tumor samples and produced
identical results. Two polyclonal antisera to PAX3 made
in rabbit (both used diluted 1:300) were generously pro-
vided by Dr. Gerald Grosveld (St. Jude’s Children’s Hospital,
Memphis, TN) and by Dr. Frank Rauscher III and Dr. William
Fredericks (Wistar Institute, Philadelphia, PA). All positive re-
sultswere confirmedusingbothPAX3antisera.Mousemono-
clonal antibodies to AP-2a (3B5; developed by Dr. Trevor
Williams) and PAX7 (PAX7; developed by Dr. Atsushi
Kawakami) were obtained from the Developmental Studies
Hybridoma Bank, developed under the auspices of the
NICHD and maintained by The University of Iowa (Iowa City,
IA). Both were used undiluted. PAX3 and PAX7 antibodies
labeled overlapping—but discrete—sets of cells, indicating
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no cross-reactivity. Antibodies to P0 (used at 1:100) and
ERBB3 (used at 1:25) were obtained (Santa Cruz Biotech-
nology). Secondary antibodies included: biotinylated goat
antimouse (Vector), biotinylated rabbit antigoat (Vector),
biotinylated goat antirabbit (Jackson Immunochemicals, West
Grove, PA), ALEXA-conjugated goat antimouse (Molecular
Probes, Eugene, OR), and ALEXA-conjugated donkey anti-
goat (Molecular Probes). To visualize biotinylated anti-
bodies, slides were treated either with the ABC Peroxidase
Kit (Vector), or, for immunofluorescence, with streptavidin
ALEXA (Molecular Probes).
Quantitative analysis of mRNA abundance was per-
formed by microarray hybridization as previously described
[31] and by quantitative PCR. For microarray analysis,
primary neuroblastoma samples were snap-frozen, and total
RNA was purified. cDNA was synthesized using T7 poly dT
primers, and in vitro transcription was performed using
biotinylated ribonucleotides. The products were then hybrid-
ized to Affymetrix human U95 microarrays and scanned
using Affymetrix Microarray Suite 4.0 or 5.0 (Affymetrix,
Santa Clara, CA).
For quantitative PCR, total RNA was purified from snap-
frozen neuroblastoma and MBL samples. One-step real-time
RT-PCR was then carried out, using various techniques.
-Actin, SOX10, and AP-2a were quantified using SYBR
green detection, on a Roche LightCycler Instrument, using
the Roche LightCycler RNA Amplification Kit (Roche Applied
Science, Indianapolis, IN, cat no. 2015137). The primers for
-actin were CCTCGCCTTTGCCGATC and CGCAGCT-
CATTGTAGAAGGTG, for SOX10 were CTGAGTTGGAC-
CAGTACCTG and GGCTGATGGTCAGAGTAGTC, and for
AP-2a were AGCAGTAGCTGAATTTCTCAAC and
TGAGGTACATTTTGTCCATG. STX was quantified using
FRET detection, on the Roche LightCycler platform, with
the Invitrogen SuperScript III Platinum One-Step RT-PCR
Kit (Invitrogen, Carlsbad, CA, cat no. 12574-018), with the
primers AGACATCTCAGAGATCGAAG and TAATATCTC-
CAGGCTTCAGG, and the probes ATGAAAGCATCAAG-
CACAACATCC-fluorescein and red640-CCAGCCTCGTCC-
AAATGGAG-phosphate.
Results
NC Markers in Human Embryos
Distinct protein expression patterns of PAX7, PAX3,
AP-2a, and SOX10 were demonstrated in truncal sections
of human embryos at 8 weeks of gestation (Figure 1, A–D).
Antibodies to PAX3, AP-2a, and SOX10 labeled NC cells
throughout the range of developmental states, from before
the beginning of migration to colonization of specific sites.
Antibodies to AP-2a and PAX3 also labeled cells not on
NC derivation. PAX3 was expressed in the dorsal neural
tube (NT), in cells along the migratory pathway by which
NC cells exit the dorsal NT, and in the dorsal root ganglia
(DRG). PAX3 was also expressed in mesodermal cells in
the dermatomyotomes (Figure 1A). AP-2a, in contrast, was
expressed in the dorsal NT only by cells at the lateral
margins, the expected location of NC cells migrating out
of the NT. Cells in the DRG and in the epithelium also
expressed AP-2a (Figure 1B). SOX10 was expressed by
NC-derived cells only outside the NT, in the DRG, in the
ventral roots, and in the para-aortic sympathetic tissue
(Figure 1C). A group of cells around the stomach, NC-
derived precursors migrating to form the enteric nervous
system, also expressed SOX10 (data not shown). In these
truncal sections, no NC-derived cells expressed PAX7.
Thus, a pattern emerged in which PAX3 was prominent in
the dorsal NT, where NC precursors begin their migration
and AP-2a and SOX10 were upregulated at progressively
farther points along the migratory pathways of the NC-
derived cells. The appearance of each marker in NC pre-
cursors and NC cells corresponded to points along their
developmental progression.
Figure 1. In truncal sections of a human embryo at approximately 8 weeks of gestation, antibodies PAX3, AP-2a, SOX10, or PAX7 specifically labeled NC-derived
cells according to their state of differentiation. Slides were labeled by immunocytochemistry using HRP and DAB, with hematoxylin counterstaining. (A) Top panel:
Antibodies to PAX3 labeled cells of the dorsal neural tube (NT), dorsal root ganglia (DRG), andmigrating NC-derived cells along an intervening trajectory (arrowhead),
while also labeling dermatomyotomal cells (arrows, lower panel). (B) Antibodies to AP-2a labeled migratory NC-derived cells as they exit the dorsal NT (black
arrowhead), aswell as cells of theDRG, the ventral root, as it leaves theNT (white arrowhead), and the embryonic epithelium (arrow). Noto = notochord. (C) Antibodies
to SOX10 labeled cells in the DRG, the dorsal and ventral roots (arrowheads), and the para-aortic sympathetic tissue (arrow). Ao = aorta. (D) Upper Panel: Antibodies
to PAX7 labeled no cells of the NT or NC at this level, but, like antibodies to PAX3, labeled cells of the dermatomyotome (arrowheads, lower panel). Bar = 100 m.
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NC Marker Expression in Mature NC-Derived Tissues
Specimens of the peripheral nerve, skin, colon, adrenal
gland, and brain were tested with antibodies to AP-2a, PAX3,
PAX7, and SOX10 to ascertain expression patterns in dif-
ferentiated NC-derived cells (Figure 2). Antibodies to SOX10
labeled Schwann cells, enteric glia, and melanocytes; also
labeled were oligodendrocytes and glial cells of NT rather
than NC derivation (Figure 2, A–D). Antibodies to PAX3
and AP-2a did not label any glial cells, but labeled melano-
cytes (Figure 2E) AP-2a, labeling all cells in the epidermis
(Figure 2F ). Antibodies to PAX7 labeled no cells in mature
tissues tested. Among NC-derived cells, therefore, glia ex-
pressed SOX10, whereas melanocytes expressed SOX10,
PAX3, and AP-2a. Enteric neurons and adrenal medullary
cells, in contrast, expressed none of themarkers.Compared to
their more widespread expression in the embryo, the expres-
sion of all three transcription factors was relatively restricted.
NC Marker Expression in Benign Neoplasms of
NC-Derived Tissues
In schwannoma and neurofibroma, benign peripheral
glial tumors, cells expressed NC transcription factors not
expressed by normal Schwann cells. Although in all cases
SOX10 was prominently expressed, as it was in mature
Schwann cells (Figure 3, A and B), schwannomas also
expressed AP-2a (three of four cases; Figure 3C), whereas
neurofibromas expressed PAX3 (six of six cases; Figure 3D).
Neither PAX3 nor PAX7 was detected in schwannomas, and
neither AP-2a nor PAX7 was detected in neurofibromas.
Thus, the two benign peripheral glial tumors expressed dif-
ferent inappropriate transcription factors, normally expressed
during peripheral glial development.
NC Marker Expression in Malignant Neoplasms of
NC-Derived Tissues and PNETs
Malignant tumors of NC lineage are diverse; we ana-
lyzed neuroblastomas [14], metastatic melanomas [3], and
malignant nerve sheath tumors (MNSTs) [4] to sample
malignant variations of a spectrum of NC-derived cell types.
Figure 2. NC markers labeled specific terminally differentiated cells, visualized by using immunocytochemistry. (A) SOX10 was expressed by Schwann cells in a
peripheral nerve (arrowheads mark examples). (B) SOX10 was expressed by enteric glia (arrowheads mark examples), seen here surrounding enteric neurons
(arrows), notable for their large unlabeled nuclei and extensive cytoplasm. (C) Oligodendrocytes in a temporal lobe section expressed SOX10. In this preparation,
SOX10 is labeled with Alexa red, GFAP is labeled with Alexa green, and nuclei are counterstained with bisbenzamide. An astrocyte (arrow) strongly expressed
GFAP, but did not express SOX10. (D) In a skin biopsy, SOX10 was expressed by melanocytes, identified by their density and position in the basal layer of the
epidermis (arrowheads mark examples). (E) Melanocytes labeled with PAX3 antibodies (arrowhead). PAX3-expressing cells were more rare than cells expressing
SOX10. (F) All cells within the epidermis expressed AP-2a. Bar = 40 m.
Figure 3. SOX10, in combination with AP-2a or PAX3, in benign glial neo-
plasms, demonstrated by immunocytochemistry. SOX10was expressed by cells
in schwannoma (A) and neurofibroma (B). Schwannoma cells expressed AP-2a
(C), whereas neurofibroma cells expressed PAX3 (D). Bar = 40 m.
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In addition, several tumors with primitive neuroectodermal
histology were analyzed: 11 MBLs (MBLs; eight classic,
three desmoplastic), 2 supratentorial primitive neuroectoder-
mal tumors (SPNETs), and 3 Ewing’s sarcomas (ES). As a
primary CNS tumors, MBL and SPNET derive from the
NT, rather than the NC. The histogenesis of ES, in contrast,
is unclear, but aspects of a NC-derived phenotype have
been noted [32].
In neuroblastoma, abnormal NC transcription factor ex-
pression was again noted in glial elements: SOX10 and
AP-2a were upregulated in elongated, Schwann-like cells,
as found in benign schwannomas (Figure 4, A and B). Neuro-
blastoma is, however, a heterogeneous set of tumors, with
variable prognoses and variable prominence of Schwann-
like cells. In addition to the relatively intense labeling of
Schwann-like cells by antibodies to SOX10 and AP-2a, a
relatively faint labeling of patches of neuroblasts was noted
in poorly differentiated tumors (Figure 4, C and D). We
analyzed three ganglioneuromas and 11 stage IV tumors.
We found SOX10 and AP-2a to be expressed in all ganglio-
neuromas, and 11 stage IV tumors, We found SOX10 and
AP-2a to be expressed in all ganglioneuromas and some
stage IV neuroblastomas, as enumerated in Table 1.
The variation in the intensity of labeling led us to compare
the abundance of SOX10 and AP-2a mRNA, determined by
both microarray hybridization and quantitative real-time
RT-PCR. Microarray data were available for all three gan-
glioneuromas included in the immunocytochemical analysis,
and for six of the stage IV neuroblastomas. SOX10 and
AP-2a mRNA were substantially more abundant in ganglio-
neuromas, where SOX10 and AP-2a where expressed only
in Schwann-like cells, than in stage IV tumors, where the
markers were expressed by neuroblasts (Figure 4; Graph 1).
The very low levels of SOX10 and AP-2a mRNA detected in
the stage IV tumors likely reflect both the low level of ex-
pression in positive cells, as seen by immunocytochemistry,
and the infrequency of patches of positive cells within the
tumor. In contrast, expression of pyruvate dehydrogenase ,
used as a control, did not vary with tumor type (Graph 1). We
found similar results using real-time RT-PCR on an over-
lapping set of six ganglioneuromas and seven stage IV neu-
roblastomas (Graph 2). Greater expression of SOX10 and
AP-2a thus correlated with glial differentiation, and lower
expression with poor differentiation.
MNSTs, like neurofibromas, expressed SOX10 and
PAX3 (Figure 5, A and C). In addition, in two of four cases,
AP-2a was detected in rare cells (Figure 5B); and in two of
four cases, PAX7 was prominently expressed (Figure 5D).
The common finding of inappropriate PAX3 expression in
neurofibroma and MNST suggests that this developmen-
tally regulated transcription factor may play a role in these
related tumors. Because it is expressed in the premalignant
lesion, PAX3 would not appear to be sufficient to confer
malignancy, but it may yet be necessary for tumor growth
and transformation.
In ES, as in MNST, exuberant expression of NC tran-
scription factors was noted: SOX10 in two of three cases,
AP-2a in two of three cases, PAX3 in three of three cases,
and PAX7 in three of three cases (Figure 5, E–H ). In mela-
noma, SOX10, AP-2a, and PAX3 were detected in almost
all cells in three of three cases (Figure 5, I–K ).
In MBL and SPNET, both intracranial PNETs, only PAX3
was detected. Using immunocytochemistry, PAX3 was
detected in classic MBL (six of eight cases) but not in the
desmoplastic variant (none of three cases). PAX3 was also
detected in one of two SPNETs. In each case, PAX3 was
expressed in discrete regions within the tumor, by almost all
cells within the regions (Figure 6, A and B).
Downstream Targets of SOX10, AP-2a, and PAX3
Corresponded with Transcription Factor Expression
Microarray data (not shown) indicated that several tar-
gets of SOX10 and AP-2a were expressed at higher levels in
Figure 4. SOX10 and AP-2a were expressed in neuroblastoma cells,
demonstrated by immunocytochemistry. In ganglioneuroma, antibodies to
SOX10 (A) or AP-2a (B) labeled elongated Schwann-like cells. In grade IV
neuroblastoma, antibodies to SOX10 (C) or AP-2a (D) labeled round,
undifferentiated cells. The labeling was weaker in cells of stage IV
neuroblastomas than ganglioneuromas. Bar = 20 mm.
Table 1. Patterns of Marker Expression.
Tissue SOX10 AP2 PAX3 PAX7
Truncal neural crest Positive Positive Positive Negative
Peripheral nerve Schwann cells Negative Negative Negative
Skin Melanocytes All cells Melanocytes Negative
Colon Enteric glia Negative Negative Negative
Adrenal medulla Negative Negative Negative Negative
Temporal lobe Oligodendrocytes Negative Negative Negative
Schwannoma 4/4 3/4 0/4 0/4
Neurofibroma 6/6 0/6 6/6 0/6
Ganglioneuroma 3/3 3/3 0/3 0/3
Neuroblastoma 8/11 2/11 0/11 0/11
MNST 4/4 2/4 4/4 2/4
Melanoma 3/3 3/3 3/3 0/3
ES 2/3 2/3 3/3 3/3
Pineal region PNET 0/2 0/2 1/2 0/2
Classic MBL 0/8 0/8 6/8 0/8
Desmoplastic MBL 0/3 0/3 0/3 0/3
Neural Crest Markers in Neuroectodermal Tumors Gershon et al. 579
Neoplasia . Vol. 7, No. 6, 2005
ganglioneuroma than in stage IV neuroblastoma. Differen-
tially expressed SOX10 targets included P0 and PLP, but not
MITF. Differentially expressed targets of AP-2a included
ERBB2 and ERBB3. Immunocytochemisrty confirmed wide-
spread expression of P0 (Figure 7A) and PLP (not shown) in
three of three ganglioneuromas, with markedly less expres-
sion in neuroblastoma (Figure 7B). Similarly, immunocyto-
chemistry confirmed widespread expression of ERBB3 in
three of three ganglioneuromas, with only rare expression
in neuroblastomas. ERBB2 was not detected with reliable
intensity in ganglioneuromas or neuroblastomas.
The finding of PAX3 in classic but not desmoplastic
MBL predicted that genes regulated by PAX3 would be dif-
ferentially expressed in classic and desmoplastic tumors.
Mayanil et al. [28] demonstrated that PAX3 positively regu-
lated the expression of several genes in the DAOY MBL
cell line, including MYOD and STX. Immunostaining did
not detect expression of MYOD in any MBLs (not shown),
whereas RT-PCR detected the expression of STX in both
classic and desmoplastic tumors. Quantitative real-time
RT-PCR, however, clearly distinguished higher expression
levels in four of four classic MBLs than in four of four
desmoplastic cases (Graph 3).
Discussion
Tumors Express NC Markers in a Manner That
Echoes Developmental Progression
Our hypothesis, that cellular programs crucial to normal
development are inappropriately activated in neuroectoder-
mal tumors, predicts that genes directing these programs
will be upregulated. We found that three genes essential
to normal NC development (PAX3, AP-2a, and SOX10)
were upregulated in a variety of neuroectodermal tumors.
Although the expression of these genes fulfills a minimal
requirement of our hypothesis, an open question is whether
they play an active role in defining tumor behavior. Although
we did not directly test the function of these genes in tumor
cells, we predicted that genes expressed earlier in NC
development would be expressed in more malignant, poorly
differentiated tumors. We tested this prediction by analyzing
the pattern of NC marker expression in embryos, differenti-
ated tissues, and neuroectodermal tumors.
We demonstrated a developmental progression in which
NC precursors express PAX3, and then migratory NC cells
express first AP-2a then SOX10. Although SOX10 is up-
regulated later in the course of NC development, the mi-
grating NC cells that begin to express it are nevertheless
proliferative and undifferentiated. Each of these markers per-
sisted in some differentiated cell types: postembryonic glia
expressed SOX10, whereas melanocytes expressed all
three NC markers. Thus, each marker participated in a spec-
trum of differentiated states. For PAX3, the range included
the least differentiated NC precursors, but also included
differentiated melanocytes. In contrast, for SOX10, the range
included the relatively differentiated migratory NC cells, and
a broader range of mature NC-derived cell types. Within this
model of NC markers defining ranges of differentiation, the
expression patterns observed in tumors fall into place.
PAX3 and MBL
The relatively early NC marker, PAX3, was upregulated
in malignant tumors in NC- or NT-derived tissues, including
melanoma, MNST, classic MBL, and SPNET. Among MBLs,
PAX3 expression distinguished classic MBL from the more
differentiated desmoplastic MBL. Although PAX3 was ex-
pressed in one benign tumor, neurofibroma, this lesion has
the potential to undergo malignant transformation to MNST.
Upregulation of PAX3 thus occurred in malignant and pre-
malignant tumors, and correlated among MBLs, with poor
differentiation. Expression of the PAX3 homologue, PAX7,
was limited more consistently to malignancies.
Graph 1. SOX10 and AP-2a mRNA, detected by microarray hybridization,
were more abundant in ganglioneuromas than in stage IV neuroblastomas.
Affymetrix intensity scores are plotted for each of the nine tumors. Lanes
1–3: Scores for ganglioneuromas; lanes 4–9: scores from stage IV neuro-
blastomas. Abundance of lactate dehydrogenase mRNA, evaluated as a
control, did not vary with tumor type.
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Although we found PAX3 to be frequently expressed in
MBL, we never found PAX3 in the desmoplastic variant.
Interestingly, this variant is associated with abnormalities of
the sonic hedgehog (SHH) signaling pathway [33], a factor
whose domain of expression is complementary to PAX3.
SHH is distributed in a gradient highest in the ventral NT [34],
whereas PAX3 is expressed in the dorsal NT. PAX3 expres-
sion thus defines a set of cells that normally do not encounter
SHH. The expression of PAX3 in MBL may thus identify a
subset of MBLs in which SHH activity is qualitatively differ-
ent. Correlation of PAX3 and genes involved in SHH signal-
ing, including SMOOTHENED, PATCHED, and GLI, would
evaluate this interpretation.
SOX10, PAX3, and Differentiation
In contrast to PAX3, the relatively late marker, SOX10,
was expressed in malignant, premalignant, and benign
tumors of NC derivation. Thus, among tumors, as in embryo-
nic and mature tissues, SOX10 expression occurred in a
range of phenotypes. In tumors, SOX10 was generally
detected in combination with other NC markers. The co-
expression of PAX3 predicted malignant phenotype or po-
tential, whereas the coexpression of SOX10 and AP-2a, in
the absence of PAX3, was seen in both malignant neuro-
blastoma and benign schwannoma and ganglioneuroma.
The finding that undifferentiated neuroblastic cells express
lower levels of SOX10 and AP-2a than the relatively dif-
ferentiated Schwann-like cells of ganglioneuroma suggests
that the dose of these transcription factors may play a role
in regulating differentiation. Similarly, other investigators
have noted the downregulation of SOX10 with malignant
transformation, in Schwann cells in vitro [35], and in MNST
biopsies [36]. It is clear, however, that although PAX3 and
SOX10 expression was consistent with a range of pheno-
types in both development and neoplasia, tumors express-
ing SOX10, but not PAX3, exhibited greater differentiation.
Specificity of Markers for NC Lineage
Expression of AP-2a, PAX3, and SOX10 in the embryo
corresponded closely with the NC lineage, as defined embry-
ologically [6]. In their fundamental dysregulation, however,
tumor cells may acquire phenotypes not appropriate for
their actual lineage, upregulating atypical genes or down-
regulating typical genes. In a humor tumor, therefore, lineage
can be at best inferred from the phenotypes of the tumor
cells and their site of origin. The expression of transcription
factors thus demonstrates not lineage, but a molecular as-
pect of phenotype. Although the expression, by tumor cells,
of AP-2a, PAX3, or SOX10 cannot establish NC lineage, it
does demonstrate a phenotypic resemblance to NC-derived
cells. The lack of expression of these markers, conversely,
does not inform as to lineage, but represents divergence
from a NC phenotype.
Our finding of the expression of multiple NC markers in
ES demonstrates a phenotypic resemblance of ES cells to
embryonic cells of NC origin. Given the similar migratory and
proliferative nature of embryonic NC-derived cells and ES
cells, their expression of common transcription factors is
likely to be significant. These transcription factors are essen-
tial for NC cell proliferation and survival, raising a question of
potential clinical importance: whether ES cells and cells of
other malignant neuroectodermal tumors share the depen-
dence of NC-derived cells for PAX3, AP-2a, and SOX10.
The expression of PAX7 in extracranial neuroectodermal
tumors is inappropriate for cells derived from truncal NC;
Graph 2. SOX10 (A) and AP-2a (B) mRNA abundance, measured by real-
time RT-PCR with SYBR green detection, was greater in ganglioneuromas
than in stage IV neuroblastomas. Each curve represents fluorescence
intensity per cycle for an individual tumor. Ganglioneuromas are shown in
shades of blue, and neuroblastomas in shades of red. Negative control with
no template is shown in gray. All ganglioneuroma curves are to the left of the
neuroblastoma curves, indicating greater abundance of specific message.
For SOX10, the average crossing point for ganglioneuroma was 18, and for
neuroblastoma was 24, indicating a 64-fold difference. For AP-2a, the
average crossing points were 25 and 30, indicating a 32-fold difference. In
contrast, -actin mRNA abundance was similar among all tumors and did not
vary with tumor type (C).
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PAX7 is normally expressed in mesoderm and cranial NC-
derived mesectoderm. We detected PAX7 in ES and MNST.
The expression of a marker inappropriate to lineage is plau-
sibly understood as the result of severe disruption of differ-
entiation in abnormal malignant cells.
Metastatic Melanoma Can Retain the Melanocytic Pattern
of NC Transcription Factors
Melanocytes expressed SOX10, AP-2a, and PAX3 si-
multaneously, a pattern otherwise observed only in malig-
nancies. The expression of these proteins persisted in the
metastatic melanomas that we analyzed. The expression
of PAX3 in melanocytes has been controversial. Using
immunocytochemistry, Galibert et al. [11] detected PAX3
in a murine melanocyte cell line. Scholl et al. [14], however,
did not find transcripts encoding PAX3 in normal melano-
cytes using in situ hybridization with oligonucleotide probes,
and concluded that PAX3 expression was specific to mela-
noma. Other investigators have correlated the loss of AP-2a
with the acquisition of metastatic behavior. The current
findings, however, indicate that PAX3 can be expressed in
normal melanocytes, whereas AP-2a can be expressed
in metastatic melanoma cells. The transformation to malig-
nancy, therefore, did not necessarily disrupt the pattern of
marker expression detected by immunocytochemistry in
normal melanocytes. The possibility remains that although
these markers were expressed at detectable levels, they
may have been present in abnormal forms, or at abnormal
Figure 5.Marker expression in melanoma, MNST, and ES cells. (A–C) Melanoma cells labeled with antibodies to SOX10 (A), AP-2a (B), and PAX3 (C). Most cells
express each of the markers. (D–G) MNST cells, labeled with antisera to SOX10 (D), AP-2a (E), PAX3 (F), and PAX7 (G). Cells expressing SOX10 and AP-2a are
relatively scattered, whereas PAX3 and PAX7 are more uniformly expressed. (H–K) ES cells labeled with antisera to SOX10 (H), AP-2a (I), PAX3 (J), and PAX7
(K). As in melanoma, markers are expressed by almost all cells. Bar = 40 m.
Figure 6. PAX3 was expressed by clusters of cells in classic MBL (A) and
SPNET (B). This patchy distribution may lead to undercounting of the cases
in which PAX3 is detected, as a small sample from a large tumor may not
include discrete regions of PAX3 expression. Bar = 40 m.
Figure 7. Expression by ganglioneuroma cells of genes regulated by SOX10
and AP-2a. P0 (A), a downstream target of SOX10, and ERBB3 (B), a down-
stream target of AP-2a, visualized by immunocytochemistry. Label was
primarily seen in elongated cells resembling Schwann cells. Bar = 20 m.
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levels, not discriminated by our methods. The detection of
these proteins in melanocytes and metastatic melanoma
cells, however, may limit their effectiveness as predictive
markers of melanoma behavior or prognosis.
SOX10, AP-2a, and the Nature of Schwann-Like Cells
in Neuroblastoma
The origin of Schwann cells within neuroblastomas has
been controversial [37–39]. Normal mature Schwann cells
expressed SOX10 but not AP-2a. In studies on rodent pe-
ripheral nerve, Stewart et al. [40] demonstrated that AP-2a
is expressed by immature Schwann cells, is downregulated as
Schwann cells mature, and is not subsequently upregulated in
response to injury or loss of axonal contacts. We found,
however, that AP-2a is expressed by Schwann-like cells in
neuroblastomas, and most prominently in ganglioneuromas.
Although our finding, that Schwann-like cells express SOX10,
is consistent with a glial phenotype, their expression of AP-2a
rather indicates that these cells are incompletely differenti-
ated. As such, these cells may be the progeny of neoplastic
cells that have retained an ability to differentiate partially. The
known association of a Schwann-like stroma with a favorable
prognosis [37,38] may thus reflect an underlying ability of
tumor cells to differentiate into stroma. Regardless of the
underlying principle, however, the current findings suggest
that expression of SOX10 and AP-2a, given their correlation
with Schwann-like stroma and with ganglioneuroma, may be a
favorable prognostic indicator.
Expression of Downstream Targets Suggests an Active
Role for NC Transcription Factors
We propose that specific NC transcription factors influ-
ence the phenotype of neuroectodermal tumors. This hy-
pothesis may ultimately be tested by genetic manipulation
in vitro, or in animal models. We sought preliminary evidence
for the effect of the NC transcription factors in the expression
of their downstream targets. As predicted, P0 and ERBB3,
respective targets of SOX10 and AP-2a, were relatively
highly expressed in ganglioneuroma, compared with stage
IV neuroblastoma. Similarly, STX, a gene upregulated by
PAX3, was relatively highly expressed in classic MBL, com-
pared with the desmoplastic variant. These findings provide
evidence that the NC transcription factors are not merely
markers of tumor phenotype, but rather determinants.
Epithelial and Mesenchymal Phenotypes in Benign and
Malignant Tumors
We predicted that PAX3, PAX7, AP-2a, and SOX10, key
elements in the genetic control of NC development, would be
expressed in tumors of NC-derived tissues and tumors of
primitive neuroectodermal histology. We found SOX10 to
be expressed in diverse tumors of NC derivation, commonly
in combination with AP-2a, PAX3, or PAX7. We also pre-
dicted that the expression of the earlier NC markers would
correlate with malignancy. We found the later NC markers,
SOX10 and AP-2a, in relatively benign neoplasms: schwan-
nomas and ganglioneuromas. In contrast, although we de-
tected PAX3 in non-neoplastic melanocytes, among tumors,
PAX3 expression coincided with malignant phenotype, or, in
the case of neurofibroma, malignant potential. Similarly,
PAX7 expression was only seen in malignant tumors.
Although PAX3 is the earliest of the NC markers tested,
and PAX7 is a close homologue, it is intriguing that both
are genes robustly expressed in mesoderm. In contrast,
SOX10 and AP-2a are restricted to ectoderm. Epithelial–
mesechymal transformation is an essential feature of early
NC development [41] that has also been implicated in malig-
nant behavior in several tumors types [42]. The relationship
between epithelial–mesenchymal transformation and the ex-
pression, in malignant NC-derived tumors, of markers ex-
pressed jointly by NC and mesodermal cells is thus striking.
In summary, we found NC markers, SOX10, AP-2a,
PAX3, and PAX7, were expressed in neuroectodermal
tumors, in a manner that varied with clinical and histo-
pathologic features, including the expression of downstream
targets. The correlation of tumor phenotype with specific NC
markers suggests that these transcription factors play a
significant role in directing tumor behavior. These findings
point to NC transcription factors as potential markers of
Graph 3. STX mRNA, measured by real-time RT-PCR with FRET detection,
was greater in classic than in desmoplastic MBLs (A). Each curve represents
intensity per cycle for an individual tumor. Classic MBLs are shown in shades
of red, and desmoplastic tumors in shades of blue. Negative control with no
template is shown in gray. All classic MBL curves are to the left of the
desmoplastic variant curves, indicating greater expression of STX mRNA.
The average crossing point for classic MBLs was 40, and for desmoplastic
tumors was 46, indicating an eight-fold difference. In contrast, -actin mRNA
abundance was similar among all tumors and did not vary with tumor type (B).
Melting point analysis revealed that the signal from the negative control in
panel (B) was due to nonspecific PCR products (not shown).
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prognosis as well as targets for therapeutic intervention for
neuroectodermal tumors.
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